Therapeutics Company Announces Royalty Sale For Up To $31.5 Million

On July 19, 2024, Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced the sale of a portion of its future royalty payments and certain milestones related to OLUMIANT® (baricitinib) to OMERS Life Sciences. This transaction, valued at up to $31.5 million, represents a move by Aclaris to bolster its financial standing and enhance its capability to invest in its diverse drug development pipeline. $Aclaris Therapeutics(ACRS.US)$